Jubilant Therapeutics Appoints Chief Scientific Officer

Jubilant Therapeutics Inc. has appointed Luca Rastelli, Ph.D. as Chief Scientific Officer, Dr. Rastelli will lead all aspects of R&D for Jubilant Therapeutics and serve as a scientific liaison for the company to investors, partners and the medical community. He reports directly to Syed Kazmi, Ph.D., Chief Executive Officer.

"Luca is a highly accomplished scientist and oncology drug developer and it is a pleasure to welcome him to the team," said Syed Kazmi, Ph.D., President and Chief Executive Officer of Jubilant Therapeutics. "His experience and leadership advancing novel targeted therapeutics will be integral as we execute our corporate vision."

"I am thrilled to join Jubilant Therapeutics and I look forward to working with the experienced management and scientific teams to further the development of the company's exciting and innovative programs into the clinic and beyond," said Luca Rastelli, Ph.D.

Dr. Rastelli brings more than 20 years of oncology drug discovery and development experience, as well as business development experience ranging from startups to large pharmaceutical companies. Most recently, he was Chief Scientific Officer at Kleo Pharmaceuticals where he led all aspects of R&D for the company and was instrumental in bringing a CD38 targeting compound based on Kleo's novel ARM technology to the clinic for multiple myeloma.

Previously Dr. Rastelli was Vice President, Oncology at BioXcel Therapeutics where he helped bring the company to a successful IPO. He has held multiple preclinical and clinical project leadership positions at Boston Scientifics, CuraGen, Sopherion and EMD Serono (Merck Serono).